Safe Sharing of Safety Studies – Procedures and Benefits
This virtual meeting will include a perspective from Thomas Steger-Hartmann (Bayer) and a discussion session.
Sharing of preclinical data among pharmaceutical companies which are otherwise perceived as competitors is both a challenging but also rewarding endeavor. The challenges which need to be overcome are legal reservations, issues around data security, standardization and curation. The benefits of data sharing lie in the development of common standards (e.g. for terminologies in the field of histopathology), the possibility to test mechanistic hypotheses and structural relationships in a wider chemical and pharmacological space and ultimately to contribute to the refinement and reduction of animal studies.